Biotech Values

[floblu14]

Friday, September 26, 2025 4:04:41 PM

Enanta Pharmaceuticals to Present Topline Results from its Phase 2b Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults
Sep 26, 2025

Conference Call and Webcast to Discuss Data on Monday, September 29 at 8:30 a.m. ET
WATERTOWN, Mass.--(BUSINESS WIRE)--Sep. 26, 2025-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced the company will hold a conference call and webcast on Monday, September 29 at 8:30 a.m. ET to share topline results from RSVHR, a Phase 2b study evaluating zelicapavir for the treatment of respiratory syncytial virus (RSV) in high-risk adults.

https://ir.enanta.com/news-releases/news-release-details/enanta-pharmaceuticals-announces-passing-its-beloved-and

9.21 - 9.30 bid & ask right now